Literature DB >> 6431348

Serum prolactin levels in patients with fibrocystic breast disease.

F Peters, W Schuth, B Scheurich, M Breckwoldt.   

Abstract

In 193 patients suffering from fibrocystic breast disease, basal serum prolactin concentrations were determined and compared to serum prolactin levels in 193 healthy women. In 45 additional patients and 23 healthy control subjects, a thyrotropin-releasing hormone (TRH) stimulation test was performed. The response to TRH in seven healthy female volunteers and in one patient with fibrocystic breast disease, was correlated with the mean serum prolactin levels over 24 hours. Serum prolactin levels were above normal in 45.6% of the patients and in 21.2% of the control subjects. Mean values of the two groups were significantly different (P less than .001). The maximum prolactin response to TRH stimulation was significantly higher in the study patients than in the control subjects (P less than .001). The TRH-stimulated prolactin response correlated positively with the mean 24-hour level (P less than .01, r = 0.8705). These results indicate that a high proportion of patients with fibrocystic breast disease exhibit increased daily prolactin secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431348

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  The endocrine basis of benign breast disorders.

Authors:  L Dogliotti; F Orlandi; A Angeli
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

Review 2.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study.

Authors:  S Gill; D Peston; B K Vonderhaar; S Shousha
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Prolactin secretion and dehydroepiandrosterone sulphate plasma levels in women with benign breast disease.

Authors:  E Parlati; I Liberale; A Travaglini; P Morelli; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

5.  Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome.

Authors:  Panchagan R K Bhargav; Anjali Mishra; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma; Saroj Kanta Mishra
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

6.  Dehydroepiandrosterone sulphate plasma levels in normal women and patients with benign breast disease.

Authors:  E Parlati; I Liberale; P Morelli; P Serva; A Travaglini; A Piccione; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

7.  Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients.

Authors:  E Parlati; A Travaglini; I Liberale; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

8.  Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat.

Authors:  Yuan-Yuei Chen; Wen-Hui Fang; Chung-Ching Wang; Tung-Wei Kao; Yaw-Wen Chang; Hui-Fang Yang; Chen-Jung Wu; Yu-Shan Sun; Wei-Liang Chen
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.